CIK in Treating Patients With Esophageal Cancer
ConditionEsophageal Squamous Cell Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-80
SponsorThe First People's Hospital of Changzhou
About this trial
Chemotherapy is the main treatment method for patients with Esophageal Cancer. However, Relapse remains the major cause of treatment failure.Biological therapies such as CIK stimulate the immune system and stop tumor cells from growing. A series of studies reported that cytokine-induced killer cells (CIK) have a broad anti-tumor spectrum. The investigators suppose that CIK will improve the prognosis. Combining chemotherapy with biological therapy may kill more tumor cells. In this study, the patients will be treated with CIK cells after chemotherapy. The purpose of this study is to evaluate the efficacy of CIK for Esophageal Cancer.
Eligibility criteria
Qualifiers
Patients histologically confirmed esophageal carcinoma;
Patients with staging I-III of esophageal carcinoma;
Patients who had completed chemotherapy;
Patients who have a life expectancy of at least 12 weeks;
Disqualifiers
Patients who had distant metastases by imaging studies;
Patients with uncontrolled infection; underlying disease that was severe or life-threatening;
Patients who were lactating;
ECOG perform status ≥ 2;
Trial design
Treatments tested in this trial
- Cytokine-induced Killer Cells
Treatment groups
2,000 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov